FIELD: pharmacology.
SUBSTANCE: invention relates to metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl) cyclopropyl]methyl]propanamide represented by compounds of formula 
II or formula 
III. The invention also relates to a pharmaceutical composition having agonistic activity for melatonin receptors comprising at least one compound selected from the group consisting of a compound of the formula II, a compound of the formula III, and a pharmaceutically acceptable carrier. The compounds of the invention are intended to treat a daily rhythm disturbance or disorder with a daily component, as well as disorders in which a melatonin agonist is indicated.
EFFECT: these metabolites are designed to treat disorders in which a melatonin agonist is shown.
5 cl, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING MAJOR DEPRESSION IN HUMAN | 2007 |
|
RU2445973C2 |
| DERIVATIVES OF BENZODIOXOL, BENZOFURAN, DIHYDROBENZOFURAN AND BENZODIOXANE AND COMPOSITIONS COMPRISING THEREOF | 1997 |
|
RU2190609C2 |
| MELATONIN AGONIST THERAPY | 2007 |
|
RU2488392C2 |
| TREATMENT OF CIRCADIAN RHYTHM VIOLATIONS | 2013 |
|
RU2631602C2 |
| TREATMENT OF CIRCADIAN RHYTHM DISORDERS | 2013 |
|
RU2650647C2 |
| ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | 2011 |
|
RU2611437C2 |
| TREATMENT OF CIRCADIAN RHYTHM DISORDERS | 2013 |
|
RU2748386C2 |
| DERIVATIVES OF N-ACYL-2-ARYLCYCLOALKYLAMINE STIMULATING MELATONIN SYNTHESIS, PHARMACEUTICAL COMPOSITION, METHOD OF MELATONIN-STIMULATING BINDING | 1996 |
|
RU2162076C2 |
| LYSIN-SPECIFIC DEMETHYLASE-1 INHIBITORS AND USE THEREOF | 2011 |
|
RU2599248C2 |
| ORGANIC COMPOUNDS | 2017 |
|
RU2733975C2 |
